Red cell exchange removes apixaban in patients with sickle cell disease
Transfusion · 2026-07 · 66 (7) · 1252-1256
DOI: 10.1111/trf.70257 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, online erschienen am 07.05.2026. Verfasst von Kimberly Boyle und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Pyridones, Anemia, Sickle Cell, Pyrazoles, Factor Xa Inhibitors. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Many patients with sickle cell disease undergo red cell exchange (RCE) and are anticoagulated with apixaban for treatment and/or prevention of venous thromboembolism. Prior studies have demonstrated that apixaban can bind to red blood cells (RBCs). However, the effect of RCE on apixaban levels is unknown. We aimed to determine if RCE alters patient plasma apixaban levels.
Methods
Plasma apixaban levels in patients were examined before/after RCE. Apixaban in the RCE collection bag and the hematocrit of the collection bag were quantified. The ability of washed RBCs from healthy donors or from patients on apixaban to inhibit FXa activity was determined using a chromogenic Direct Xa Inhibitor kit.
Results
Seven patients underwent 72 RCE. Plasma apixaban levels declined significantly after RCE (mean decline in apixaban level 68.1 ± 20.7%, p < 0.0001). Apixaban was present in the plasma/supernatant of all RCE collection bags tested. The percent decline in patient plasma apixaban levels after RCE was weakly correlated with the hematocrit of the RCE collection bag ( r = 0.36, p = ns). Incubation of FXa with RBCs from patients on apixaban resulted in significantly less FXa activity compared to RBCs from healthy donors (mean Xa activity [A405 nm] of healthy RBC 0.79 ± 1.8 vs. apixaban RBC 0.54 ± 0.22, p = 0.005).
Discussion
We provide the first description of apixaban removal with RCE. Removal of apixaban is occurring via removal of incidental plasma and of RBC‐bound drug and can result in undetectable drug levels in this high‐risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
- Department of Apheresis, Duke University Medical Center, Durham, North Carolina, USA.
- Department of Perioperative Services, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
- Clinical Coagulation, Duke University Hospital Laboratories, Durham, North Carolina, USA.
- Duke Molecular Physiology Institute, Duke University Medical Center, Durham, North Carolina, USA.
ORCID-Profile: Grace M Lee
Zitieren
APA
Boyle, K., Evans, M., Mansfield, C., Notini, M., Garrett, M. E., Arepally, G. M., & Lee, G. M. (2026). Red cell exchange removes apixaban in patients with sickle cell disease. Transfusion, 66(7), 1252-1256. https://doi.org/10.1111/trf.70257
Vancouver
Boyle K, Evans M, Mansfield C, Notini M, Garrett ME, Arepally GM, et al. Red cell exchange removes apixaban in patients with sickle cell disease. Transfusion. 2026;66(7):1252-1256. doi:10.1111/trf.70257
BibTeX
@article{Boyle2026,
author = {Boyle, Kimberly and Evans, Mary and Mansfield, Coral and Notini, Maria and Garrett, Melanie E and Arepally, Gowthami M and Lee, Grace M},
title = {Red cell exchange removes apixaban in patients with sickle cell disease},
journal = {Transfusion},
year = {2026},
volume = {66},
number = {7},
pages = {1252--1256},
doi = {10.1111/trf.70257}
}
EUVIMED